Company Welcomes Janette Phi as Chief Operations Officer

SAN FRANCISCO–(BUSINESS WIRE)–January 4, 2018–

Xcell Biosciences introduced right now that it has expanded its improvement and business efforts round new market alternatives in immunotherapy drug analysis and improvement. The ever-growing Immuno-Oncology panorama and demonstrated success of recent immunotherapy remedies has led to a big demand for instruments and programs to increase and management major tumor and immune cells for each analysis and medical purposes. Mature and stem cell-derived major cells are additionally wanted for assessing off-target results for immunotherapy improvement. Xcell will use its experience in increasing and modulating phenotypes of major tumor, stem cell, and immune populations to ship a brand new set of purposes tailor-made to the immunotherapy and cell remedy drug improvement and manufacturing markets.

In addition to this expanded market focus, Xcell Biosciences welcomed Janette Phi to the group because the Chief Operations Officer.

“We are thrilled to have Janette be a part of the Xcell Biosciences crew. Janette brings an immense quantity of expertise in Commercial Development and enterprise management to the crew, coupled with a robust background in immunology and normal cell biology,” mentioned Brian S. Feth, Chief Executive Officer at Xcell Biosciences. “Her steering has helped us to focus our priorities, refine our message and is enabling us to drive our know-how into essential new markets.”

Prior to becoming a member of Xcell, Ms. Phi was Chief Business Officer and Chief Commercial Officer at IntelliCyt Corporation (a Sartorius Company). She has over 25 years of expertise within the life sciences, coupled with intensive medical expertise. In addition to her management roles at IntelliCyt, Janette beforehand held administration positions at ForteBio, Guava Technologies, AmCell and Becton Dickinson Biosciences.

“I’m very excited to hitch the Xcell crew in globally launching this proprietary, transformative know-how to the sector of immunotherapy,” Ms. Phi said. “The know-how has demonstrated its potential impression in cell remedy improvement by way of management of the physiological microenvironment, enabling predictive affected person responses in precision most cancers medication.”

About Xcell Biosciences, Inc.

Xcell Biosciences, Inc., is creating revolutionary merchandise and workflows that empower scientists in essential fields together with most cancers analysis, immunology, stem cell biology, and cell remedy improvement. With $12 Million Series A from buyers together with HBM Genomics, Viking Global, Passport, Lightspeed, and Illumina; Xcell’s first product, the Avatar™ cell management system, presents a robust new device permitting for full management of key physiological circumstances present in mobile microenvironments, enabling speedy optimization of exact circumstances to obtain long-term cell upkeep, enlargement, and phenotypes of curiosity. For extra data, go to www.xcellbio.com.

Xcell Biosciences
Kaitie Kramer, 858-504-0455
kaitie@xcellbio.com

This article sources data from VentureBeat